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ABSTRACT
The P2Y12 receptor is the molecular target for thienopyridines, namely clopidogrel and prasugrel, of which 
the active metabolites formed in the liver covalently bind to the P2Y12 receptor and also for direct, revers-
ible antagonists such as ticagrelor, cangrelor, and elinogrel. There are several limitations of P2Y12 orally 
administered inhibitors especially if used in patients with acute coronary syndrome treated with PCI. Can-
grelor has the advantage over all orally administered agents of being a very potent, quickly reversible and 
direct-acting P2Y12 antagonist, reaching consistent optimal platelet inhibition minutes after the start of the 
infusion. The results of three major currently available clinical trials (CHAMPION PLATFORM, CHAMPION 
PCI, and CHAMPION PHOENIX) show cangrelor to be relatively safe and more effective than clopidogrel 
in patients with acute coronary syndromes and undergoing coronary interventions. The BRIDGE study 
demonstrated the feasibility of the use of cangrelor as a bridging therapy in patients awaiting cardiac 
surgery who require prolonged platelet P2Y12 inhibition. 
Cangrelor is not available yet; however, the pharmacodynamic properties of cangrelor (prompt and potent 
onset of action and fast offset) make it a desirable drug in an emergency setting, particularly in patients 
undergoing coronary interventions and in patients awaiting cardiac surgery who require prolonged plate-
let inhibition.
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The initiation of thrombus formation caused by 
vessel wall injury is mediated by von Willebrand factor 
bound to subendothelial matrix. The formation of a sta-
ble thrombus requires integrin activation, a process in 
which P2Y12 plays an important role [1]. Downstream 
signalling events of the P2Y12 receptor are essential for 
platelet full aggregation and thromboxane generation 
induced by other agonists [2, 3]. 
Because of the critical role of P2Y12 in platelet ac-
tivation, compounds which target this platelet receptor 
have been developed and widely used in the prevention 
and treatment of thrombotic events [3–5]. Blockade of 
the P2Y12 receptor prevents initial activation and am-
plification of responses to platelet stimuli while leaving 
the final common pathway of platelet aggregation in-
tact. Moreover, blockade of this receptor inhibits other 
platelet-derived proaggregatory, procoagulant, and 
proinflammatory factors that may have an additional 
impact on the clinical outcome [6]. This receptor is the 
molecular target for thienopyridines: i.e. clopidogrel and 
prasugrel, of which the active metabolites formed in the 
liver covalently bind to the P2Y12 receptor [7, 8], as well 
as the molecular target for direct, reversible antagonists 
such as ticagrelor, cangrelor, and elinogrel [9–11]. 
There are several limitations of P2Y12 orally admin-
istered inhibitors especially if used in patients with acute 
coronary syndromes (ACS) treated with PCI. Inter-indi-
vidual variability of the pharmacokinetic and pharma-
codynamic response, widely described for clopido-
grel, is one of the most important limitations [12–14]. 
Several studies have demonstrated that a substantial 
subset of patients treated with dual antiplatelet therapy 
with aspirin and clopidogrel do not reach adequate 
levels of platelet inhibition at the time of PCI [15, 16]. 
Moreover, these patients are at a higher risk for the 
occurrence of atherothrombotic events [17–21]. The 
PLATO study and the TRITON study provided evidence 
that the more potent effect of ticagrelor as well as prasu-
grel on P2Y12 inhibition results in a significant reduction 
of athero-thrombotic events compared to clopidogrel 
in patients with acute coronary syndromes [4, 5]. 
However, even treatment with oral antiplatelet agents 
that are more potent then clopidogrel,  such as prasu-
grel and ticagrelor, may not result in maximal platelet 
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inhibition in high-risk patients undergoing PCI [22, 23]. 
Oral P2Y12 inhibitors cannot provide reliable inhibition 
in patients who are unable to swallow or rapidly absorb 
medication taken orally, such as those who are sedat-
ed, intubated, in shock, or with nausea or vomiting. 
In patients with ST-segment elevation MI (STEMI), 
nausea has been reported in almost two thirds of all 
patients and vomiting in nearly one third [24, 25]. These 
limitations, of particular importance in the acute care 
setting, prompted the investigation for a novel effective 
P2Y12 inhibitor [26]. 
Cangrelor has the advantage over all orally admin-
istered agents of being a very potent, quickly reversible 
and direct-acting P2Y12 antagonist, reaching consistent 
optimal platelet inhibition minutes after the start of the 
infusion [14, 27]. 
Unlike thienopyridines, it does not require hepatic 
activation. The very rapid onset of action of cangrelor is 
the result of intravenous administration and small initial 
volume of distribution restricted to the blood compart-
ment [28]. The drug is rapidly metabolised through 
dephosphorylation by an endonucleotidase located on 
the surface of vascular endothelial cells with an elim-
ination half-life of 2.9 to 5.5 minutes. The rapid on-off 
feature of cangrelor enables temporary suppression of 
platelet activation on top of oral antiplatelet treatment 
during PCI [29, 30]. 
Steinhubl et al. [31] described the interaction 
between clopidogrel and cangrelor in healthy vol-
unteers. A bolus and infusion of cangrelor provided 
immediate and almost complete inhibition of platelet 
aggregation, and activation rapidly reversed upon ter-
mination of the infusion. A loading dose of clopidogrel, 
given alone or started immediately after a cangrelor 
infusion, led to the anticipated degree of platelet inhi-
bition after about 2 h. However, when both drugs were 
administered simultaneously, clopidogrel was unable 
to inhibit platelet aggregation. These observations sug-
gest that cangrelor’s high affinity for the P2Y12 receptor 
prohibits clopidogrel’s active metabolite from forming 
the necessary disulfide bridge with cysteine residues in 
the extracellular domain of this receptor [7, 31]. 
Ravnefjord et al. [32] reported a lack of interaction 
between cangrelor and ticagrelor. The mechanism of 
action of reversible inhibitors is similar and inhibition of 
platelet aggregation (IPA) reflects plasma concentra-
tions of these agents. Thus, when a cangrelor infusion 
is stopped and rapidly cleared from the plasma, tica-
grelor binds to the receptors as they become available 
maintaining P2Y12 antagonism [31]. 
These findings have potentially important clinical 
implications, because patients treated with cangrelor, in 
particular those undergoing a PCI, would be expected to 
continue long-term oral platelet P2Y12 inhibition [33, 34]. 
Initiation of oral therapy with a thienopyridine before 
termination of a cangrelor infusion may result in an 
important gap in platelet inhibition. This might be 
particularly critical following stent placement. Thus, to 
achieve sustained platelet inhibition in patients treated 
with cangrelor, the administration of irreversible, oral 
P2Y12 antagonists should be started after the cangrelor 
infusion has been terminated [31, 35–37]. On the other 
hand, lack of interaction between cangrelor and tica-
grelor may suggest choosing the latter for maintenance 
treatment if cangrelor was used in the acute setting. This 
however should be clinically tested.
The results of three major clinical trials regarding 
the use of cangrelor in patients with acute coronary 
syndromes and undergoing coronary interventions 
are currently available: CHAMPION PLATFORM [38], 
CHAMPION PCI [39], and CHAMPION PHOENIX [40].
Both the CHAMPION PLATFORM [38] and CHAM- 
PION PCI [39] trials were prematurely stopped, follow-
ing a decision by the interim analysis review committee 
that the studies would not show the persuasive clinical 
efficacy of cangrelor. Despite favourable pharmacody-
namic properties, cangrelor was not superior to clopi-
dogrel in reducing the incidence of ischaemic events 
in either of these CHAMPION trials [38, 39]. 
Taken together, both CHAMPION trials may provide 
an insight into the optimal timing of periprocedural 
antiplatelet blockade with clopidogrel [38, 39, 41]. The 
examination of secondary composite endpoints suggests 
a more robust effect in the CHAMPION PLATFORM trial 
(600 mg of clopidogrel at the end of the procedure) 
than in the CHAMPION PCI trial (600 mg of clopidogrel 
at the beginning of the procedure), though this is only 
a speculative observation. 
As both CHAMPION studies used similar inclu-
sion/exclusion criteria, and death, myocardial infarc-
tion, or ischaemia-driven revascularisation (including 
stent thrombosis) at 48 hours were their primary 
endpoints, the studies were pooled [41]. A total of 
13,049 patients were included. No effect of cangrelor 
with regard to the primary endpoint was revealed with 
the original MI definition. However, after application 
of the new universal definition of MI, a significant 
reduction of the primary endpoint with cangrelor 
compared to a 600-mg loading dose of clopidogrel 
was observed (3.1% cangrelor vs 3.8% clopidogrel; 
OR 0.82 [95% CI 0.68–0.99], P = 0.037). Regarding 
safety measures, there was an increase in clinically 
significant bleedings using the ACUITY scale with can-
grelor, mainly because of the increased occurrence 
of groin haematomas [38, 39, 41]. 
The knowledge gained in CHAMPION PLATFORM 
[38] and in CHAMPION PCI [39] resulted in new 
questions to be answered, leading to the CHAMPION 
PHOENIX trial [40]. In this, a total of 10,942 patients 
requiring PCI for stable angina or acute coronary 
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syndrome were enrolled and received an infusion of 
cangrelor or placebo. Patients treated with cangrelor 
obtained a loading dose of clopidogrel at the end of 
infusion, while patients receiving placebo obtained 
a loading dose of clopidogrel at the time of the PCI 
procedure. Treatment during the procedure was 
followed by a standard maintenance dose of an oral 
P2Y12 inhibitor and aspirin. The rate of the primary 
composite efficacy endpoint of death from any cause, 
myocardial infarction (according to the universal defi-
nition of MI), ischaemia-driven revascularisation, or 
stent thrombosis at 48 hours, was significantly lower 
in the cangrelor group than in the clopidogrel group. 
The observed reduction of ischaemic event odds of 
22% in patients treated with cangrelor was not accom-
panied by a significant increase in severe bleeding or 
in the need for transfusions compared to patients on 
clopidogrel [40]. 
Cangrelor has been shown to be relatively safe 
and more effective than clopidogrel in patients treated 
with PCI for stable coronary artery disease and acute 
coronary syndromes. 
Currently available oral P2Y12 inhibitors may 
increase the risk for bleeding in patients requiring 
urgent surgical revascularisation. On the other hand, 
cessation of the antiplatelet therapy for nearly a week 
before surgery, necessary in patients on oral P2Y12 in-
hibitors, carries a greater risk of serious ischaemic 
events [4, 5, 29, 42]. 
The BRIDGE study demonstrated the feasibility of 
the use of cangrelor for bridging therapy in patients 
waiting for cardiac surgery who require prolonged 
platelet P2Y12 inhibition [43]. Another approach 
proposed for a bridging strategy with the use of small 
molecule glycoprotein IIb/IIIa inhibitors, in particular 
tirofiban and eptifibatide, presents some of the advan-
tages of cangrelor including the rapid onset of action 
as well as consistent and strong platelet inhibition. 
However, tirofiban and eptifibatide have a slower off-
set of action, requiring 4-6 hours to return to baseline 
platelet function, while only one hour is required in 
patients treated with cangrelor. Moreover, both these 
Gp IIb/IIIa inhibitors used at doses recommended for 
ACS treatment are associated with increased bleeding 
risk [43, 44]. 
Extracorporeal circulation and hypothermia are 
routinely used in an emergency setting. Both these 
procedures cause platelet activation and dysfunction, 
possibly followed by bleeding and thromboembolic 
complications [45]. Despite the promising results of 
initial research, knowledge regarding the efficacy of 
cangrelor in these specific subsets of patients is limi - 
ted [46]. However, due to very potent platelet inhibition, 
this agent may be very useful in clinical situations lead-
ing to an increase in platelet reactivity.
Conclusion
Cangrelor is not available yet in routine clinical 
practice, however the pharmacodynamic properties 
of cangrelor (prompt and potent onset of action and 
fast offset) make it a desirable drug in an emergency 
setting, particularly in patients undergoing coronary 
interventions and in patients awaiting cardiac surgery 
who require prolonged platelet inhibition.
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